Skip to main content

Table 4 Post-index healthcare utilization among patients with 12 months of continuous enrollment post-index

From: Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

  All Patients Pirfenidone Nintedanib P Value1
N = 614 N = 348 N = 266
All-cause utilization
 Inpatient hospitalization2, n (%) 156 (25.4) 91 (26.1) 65 (24.4) 0.629
  Length of stay, mean (SD), days 4.4 (3.7) 4.2 (3.5) 4.8 (4.1) 0.263
   Median 3 3 3.5  
 Any outpatient visit, n (%) 610 (99.1) 346 (99.4) 264 (99.2) 1.000
  Emergency department visit 206 (33.6) 112 (32.2) 94 (35.3) 0.412
  Physician office visit 600 (97.7) 340 (97.7) 260 (97.7) 0.972
 Pharmacy, n (%) 614 (100.0) 348 (100.0) 266 (100.0) 1.000
  Medication claims PPPY, mean (SD) 49.6 (27.0) 49.7 (26.4) 49.5 (27.8) 0.938
Respiratory-related utilization
 Inpatient hospitalization2, n (%) 70 (11.4) 45 (12.9) 25 (9.4) 0.172
  Length of stay, mean (SD), days 4.9 (4.1) 4.1 (2.9) 6.3 (5.4) 0.033
   Median 4 3.5 4  
 Any outpatient visit, n (%) 607 (98.9) 343 (98.6) 264 (99.2) 0.705
  Emergency department visit 116 (18.9) 64 (18.4) 52 (19.5) 0.716
  Physician office visit 597 (97.2) 338 (97.1) 259 (97.4) 0.856
 Pharmacy, n (%) 614 (100.0) 348 (100.0) 266 (100.0) 1.000
  Medication claims PPPY, mean (SD) 14.6 (8.0) 14.4 (7.5) 14.8 (8.6) 0.517
  1. PPPY per-person per-year, SD standard deviation
  2. 1 Pirfenidone vs. nintedanib
  3. 2 Excluding inpatient hospitalizations for a lung transplant